| # | Title | Journal | Year | Citations |
|---|
| 1 | The intestinal barrier: a fundamental role in health and disease | Expert Review of Gastroenterology and Hepatology | 2017 | 703 |
| 2 | Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal | Expert Review of Gastroenterology and Hepatology | 2009 | 326 |
| 3 | The evolving epidemiology of hepatocellular carcinoma: a global perspective | Expert Review of Gastroenterology and Hepatology | 2015 | 305 |
| 4 | Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics | Expert Review of Gastroenterology and Hepatology | 2009 | 259 |
| 5 | Assessing portal hypertension in liver diseases | Expert Review of Gastroenterology and Hepatology | 2013 | 241 |
| 6 | Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications | Expert Review of Gastroenterology and Hepatology | 2011 | 197 |
| 7 | Autophagy in nonalcoholic steatohepatitis | Expert Review of Gastroenterology and Hepatology | 2011 | 193 |
| 8 | Update on hepatic stellate cells: pathogenic role in liver fibrosis and novel isolation techniques | Expert Review of Gastroenterology and Hepatology | 2012 | 153 |
| 9 | An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation | Expert Review of Gastroenterology and Hepatology | 2020 | 148 |
| 10 | The growing incidence and severity ofClostridium difficileinfection in inpatient and outpatient settings | Expert Review of Gastroenterology and Hepatology | 2010 | 142 |
| 11 | Obesity, diabetes, and the gut microbiome: an updated review | Expert Review of Gastroenterology and Hepatology | 2019 | 139 |
| 12 | Obesity and the microbiome | Expert Review of Gastroenterology and Hepatology | 2015 | 127 |
| 13 | Chemokine-directed immune cell infiltration in acute and chronic liver disease | Expert Review of Gastroenterology and Hepatology | 2008 | 118 |
| 14 | Diagnosis of hepatitis B virus infection through serological and virological markers | Expert Review of Gastroenterology and Hepatology | 2008 | 117 |
| 15 | The role of hypoxia in pancreatic cancer: a potential therapeutic target? | Expert Review of Gastroenterology and Hepatology | 2016 | 114 |
| 16 | Advances in liver regeneration | Expert Review of Gastroenterology and Hepatology | 2014 | 112 |
| 17 | Update on the pathophysiology of liver fibrosis | Expert Review of Gastroenterology and Hepatology | 2010 | 108 |
| 18 | Mycobacterium paratuberculosis as a cause of Crohn’s disease | Expert Review of Gastroenterology and Hepatology | 2015 | 108 |
| 19 | Extraintestinal manifestations in inflammatory bowel disease – epidemiology, genetics, and pathogenesis | Expert Review of Gastroenterology and Hepatology | 2019 | 108 |
| 20 | Current epidemiology in hepatocellular carcinoma | Expert Review of Gastroenterology and Hepatology | 2021 | 107 |
| 21 | The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis | Expert Review of Gastroenterology and Hepatology | 2018 | 103 |
| 22 | Management of giant liver hemangiomas: an update | Expert Review of Gastroenterology and Hepatology | 2013 | 102 |
| 23 | Nutritional consequences of celiac disease and the gluten-free diet | Expert Review of Gastroenterology and Hepatology | 2014 | 102 |
| 24 | Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications | Expert Review of Gastroenterology and Hepatology | 2015 | 102 |
| 25 | Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study | Expert Review of Gastroenterology and Hepatology | 2015 | 100 |
| 26 | Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea | Expert Review of Gastroenterology and Hepatology | 2015 | 100 |
| 27 | Fermentable oligosaccharides, disaccharides, monosaccharides and polyols: role in irritable bowel syndrome | Expert Review of Gastroenterology and Hepatology | 2014 | 99 |
| 28 | Microbiota and mucosal defense in IBD: an update | Expert Review of Gastroenterology and Hepatology | 2019 | 98 |
| 29 | Cells, cytokines and inflammatory bowel disease: a clinical perspective | Expert Review of Gastroenterology and Hepatology | 2011 | 96 |
| 30 | Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications | Expert Review of Gastroenterology and Hepatology | 2018 | 95 |
| 31 | Rebamipide: a gastrointestinal protective drug with pleiotropic activities | Expert Review of Gastroenterology and Hepatology | 2010 | 91 |
| 32 | Existing dietary guidelines for Crohn’s disease and ulcerative colitis | Expert Review of Gastroenterology and Hepatology | 2011 | 91 |
| 33 | Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers | Expert Review of Gastroenterology and Hepatology | 2019 | 88 |
| 34 | GM-CSF: a role in immune and inflammatory reactions in the intestine | Expert Review of Gastroenterology and Hepatology | 2010 | 87 |
| 35 | Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients | Expert Review of Gastroenterology and Hepatology | 2011 | 86 |
| 36 | QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? | Expert Review of Gastroenterology and Hepatology | 2012 | 86 |
| 37 | Eosinophilic gastroenteritis: an update | Expert Review of Gastroenterology and Hepatology | 2012 | 85 |
| 38 | A global burden of gastric cancer: the major impact of China | Expert Review of Gastroenterology and Hepatology | 2017 | 85 |
| 39 | Recent advances of immunotherapy for biliary tract cancer | Expert Review of Gastroenterology and Hepatology | 2021 | 85 |
| 40 | Extended-criteria donors in liver transplantation Part II: reviewing the impact of extended-criteria donors on the complications and outcomes of liver transplantation | Expert Review of Gastroenterology and Hepatology | 2016 | 83 |
| 41 | Gut microbiota changes and chronic hepatitis C virus infection | Expert Review of Gastroenterology and Hepatology | 2017 | 83 |
| 42 | Acute-on-chronic liver failure in chronic hepatitis B: an update | Expert Review of Gastroenterology and Hepatology | 2018 | 83 |
| 43 | The use of fecal calprotectin as a biomarker in gastrointestinal disease | Expert Review of Gastroenterology and Hepatology | 2014 | 82 |
| 44 | Adverse events in IBD: to stop or continue immune suppressant and biologic treatment | Expert Review of Gastroenterology and Hepatology | 2014 | 82 |
| 45 | Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review | Expert Review of Gastroenterology and Hepatology | 2016 | 82 |
| 46 | Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease | Expert Review of Gastroenterology and Hepatology | 2019 | 82 |
| 47 | Advances in antifibrotic therapy | Expert Review of Gastroenterology and Hepatology | 2008 | 81 |
| 48 | The IL-23/IL-17 pathway in inflammatory bowel disease | Expert Review of Gastroenterology and Hepatology | 2012 | 81 |
| 49 | Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions | Expert Review of Gastroenterology and Hepatology | 2011 | 80 |
| 50 | The pediatric Rome IV criteria: what’s new? | Expert Review of Gastroenterology and Hepatology | 2017 | 80 |
